Amy Welsh - 01 Nov 2022 Form 3 Insider Report for AGILE THERAPEUTICS INC (AGRX)

Role
Chief Commercial Officer
Signature
/s/ Geoffrey P. Gilmore Attorney-in-Fact
Issuer symbol
AGRX
Transactions as of
01 Nov 2022
Net transactions value
$0
Form type
3
Filing time
09 Nov 2022, 16:05:31 UTC
Next filing
14 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGRX Employee Stock Option (Right to Buy) 01 Nov 2022 Common Stock 1,500 $95.60 Direct F1
holding AGRX Employee Stock Option (Right to Buy) 01 Nov 2022 Common Stock 1,000 $112.80 Direct F2
holding AGRX Employee Stock Option (Right to Buy) 01 Nov 2022 Common Stock 1,000 $13.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on April 27, 2020. 25% of the shares subject to the stock option vested on April 27, 2021, and the remaining shares vest in 36 equal monthly installments over the following three years, such that the option will be fully vested by April 27, 2024.
F2 This option was granted on January 27, 2021. 25% of the shares subject to the stock option vested on January 27, 2022, and the remaining shares vest in 36 monthly installments over the following three years, such that the option will be fully vested by January 27, 2025.
F3 This option was granted on January 19, 2022. 25% of the shares subject to the stock option vest on January 19, 2023, and the remaining shares vest in 36 equal monthly installments over the following three years, such that the option will be fully vested by January 19, 2026.

Remarks:

Exhibit List 24.1 - Power of Attorney